GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: GSK1322322
Compound class:
Synthetic organic
Comment: Lanopepden is a first-in-class antibacterial that targets peptide deformylase (PDF), a bacterial enzyme essential for protein maturation [3-4].
|
|
|||||||||||||||||||||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Lanopepden was progressed to Phase 2 evaluation (NCT01209078) as a treatment for acute bacterial skin and skin structure infections (ABSSSI). However, GlaxoSmithKline terminated development due to potentially reactive metabolites found in nonclinical studies [2]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01209078 | GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection | Phase 2 Interventional | GlaxoSmithKline | 1 | |